TMF/ARA160 downregulates proangiogenic genes and attenuates the progression of PC3 xenografts

International Journal of Cancer

Volumn 125, Issue 1, 2009, Pages 43-53

  Abrham, Galya ^a   Volpe, Marina ^a   Shpungin, Sally ^a   Nir, Uri ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARA 160 TRANSCRIPTION FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; STAT3 PROTEIN; TATA ELEMENT MODULATORY FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MESSENGER RNA; PRIMER DNA; PROTEASOME; RELA PROTEIN, MOUSE; SMALL INTERFERING RNA; TMF1 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; CANCER GROWTH; CARCINOMA CELL; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METABOLIC STRESS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; UBIQUITINATION; WESTERN BLOTTING; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE COURSE; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NICK END LABELING; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TATA BOX;

ANIMALS; BLOTTING, WESTERN; DISEASE PROGRESSION; DNA PRIMERS; DNA-BINDING PROTEINS; DOWN-REGULATION; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INTERLEUKIN-1BETA; INTERLEUKIN-8; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TATA BOX; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS; TRANSPLANTATION, HETEROLOGOUS; UBIQUITINATION;

EID: 66149121840     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24277     Document Type: Article

References (45)

1. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, Foretz M, Viollet B. 50-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006;26:5336-47.
2. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Mori K, Kato H. A putative nuclear receptor coactivator (TMF/ARA160) associates with hbrm/hSNF2 alpha and BRG-1/hSNF2 beta and localizes in the Golgi apparatus. FEBS Lett 2002;520:127-32.
4. Fridmann-Sirkis Y, Siniossoglou S, Pelham HR. TMF is a golgin that binds Rab6 and influences Golgi morphology. BMC Cell Biol 2004;5:18.
5. Yamane J, Kubo A, Nakayama K, Yuba-Kubo A, Katsuno T, Tsukita S, Tsukita S. Functional involvement of TMF/ARA160 in Rab6-dependent retrograde membrane traffic. Exp Cell Res 2007;313:3472-85.
6. Garcia JA, Ou SH, Wu F, Lusis AJ, Sparkes RS, Gaynor RB. Cloning and chromosomal mapping of a human immunodeficiency virus 1 "TATA" element modulatory factor. Proc Natl Acad Sci USA 1992;89:9372-6.
7. Hsiao PW, Chang C. Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells. J Biol Chem 1999;274:22373-9.
8. Perry E, Tsruya R, Levitsky P, Pomp O, Taller M, Weisberg S, Parris W, Kulkarni S, Malovani H, Pawson T, Shpungin S, Nir U. TMF/ARA160 is a BC-box-containing protein that mediates the degradation of Stat3. Oncogene 2004;23:8908-19.
9. Volpe M, Shpungin S, Barbi C, Abrham G, Malovani H, Wides R, Nir U. trnp: a conserved mammalian gene encoding a nuclear protein that accelerates cell-cycle progression. DNA Cell Biol 2006;25:331-9.
10. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000;42:186-95.
11. Schwartz Y, Ben-Dor I, Navon A, Motro B, Nir U. Tyrosine phosphorylation of the TATA element modulatory factor by the FER nuclear tyrosine kinases. FEBS Lett 1998;434:339-45.
12. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J, Eshhar Z. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res 2000;60:6563-7.
13. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for annotation, visualization, and integrated, discovery. Genome Biol 2003;4:R60.
14. Hosack DA, Dennis G, Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
15. Treier M, Staszewski LM, Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 1994;78:787-98.
16. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
17. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-608.
18. Zhao X, Sun Y, Yu H, Ye L, Zhang L, Lu J, Yuan Y, Qian G, Ge S. Apoptosis induced by BIK was decreased with RNA interference of caspase-12. Biochem Biophys Res Commun 2007;359:896-901.
19. Hur J, Bell DW, Dean KL, Coser KR, Hilario PC, Okimoto RA, Tobey EM, Smith SL, Isselbacher KJ, Shioda T. Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res 2006;66:10153-61.
20. Hur J, Chesnes J, Coser KR, Lee RS, Geck P, Isselbacher KJ, Shioda T. The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc Natl Acad Sci USA 2004;101:2351-6.
21. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 2002;12:197-207.
22. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
23. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S, Kimura YN, Hamano S, Sonoda KH, Saijo Y, Nukiwa T, Strieter RM, Ishibashi T, Kuwano M, et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 2005;115:2979-91.
24. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 2007;29:19-35.
25. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W, Banerjee A. Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 2006;25:6781-99.
26. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 1997;14:2809-16.
27. Assuncao GC, Linden R. Programmed cell deaths. Apoptosis and alternative deathstyles. Eur J Biochem 2004;271:1638-50.
28. Ljungman M, Lane DP. Transcription-guarding the genome by sensing DNA damage. Nat Rev Cancer 2004;4:727-37.
29. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol Lett 2004;149:19-23.
30. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004;25:259-64.
31. Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005;11:6333-41.
32. Kim ND, Im E, Yoo YH, Choi YH. Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids. Curr Cancer Drug Targets 2006;6:681-9.
33. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319-29.
34. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60.
35. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008;28:185-200.
36. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 1998;51:55-61.
37. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, Rottapel R, Yamaoka S, Lu KP. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-26.
38. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med 2004;200:107-13.
39. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007;8:584-91.
40. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003;159:283-300.
41. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6:2573-81.
42. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001;21:3964-73.
43. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
44. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
45. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E, Carturan S, Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006;20:61-7.